Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avanos Medical (AVNS) Intangibles (2016 - 2026)

Avanos Medical's Intangibles history spans 13 years, with the latest figure at $117.8 million for Q4 2025.

  • On a quarterly basis, Intangibles rose 4.9% to $117.8 million in Q4 2025 year-over-year; TTM through Dec 2025 was $117.8 million, a 4.9% increase, with the full-year FY2025 number at $117.8 million, up 4.9% from a year prior.
  • Intangibles hit $117.8 million in Q4 2025 for Avanos Medical, down from $122.0 million in the prior quarter.
  • Over the last five years, Intangibles for AVNS hit a ceiling of $271.1 million in Q1 2022 and a floor of $105.4 million in Q2 2025.
  • Historically, Intangibles has averaged $190.6 million across 5 years, with a median of $221.4 million in 2023.
  • Biggest five-year swings in Intangibles: skyrocketed 78.05% in 2022 and later crashed 53.95% in 2025.
  • Tracing AVNS's Intangibles over 5 years: stood at $141.2 million in 2021, then surged by 65.86% to $234.2 million in 2022, then grew by 2.26% to $239.5 million in 2023, then plummeted by 53.11% to $112.3 million in 2024, then grew by 4.9% to $117.8 million in 2025.
  • Business Quant data shows Intangibles for AVNS at $117.8 million in Q4 2025, $122.0 million in Q3 2025, and $105.4 million in Q2 2025.